Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
about
Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimodChemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cellsVisual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknownRedox-based therapeutics in neurodegenerative disease.Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple SclerosisDimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes.Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis.Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion.Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis.Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients.JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy-related intracranial effects.ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphat
P2860
Q26740235-EEA038C7-2369-4D53-9F25-C5C2FE616399Q28821775-816EBA02-8E8C-44AA-881F-10F010C58AF6Q33875468-DC0DB949-A446-48C9-9948-BF16ACB11222Q34535918-E10F4C71-1AD3-497A-AD9D-6F135B6812E1Q36484448-192D1D97-0E0A-4CE1-A0DF-7DCCC5C72B7CQ37262461-E7937FBE-DF43-48F8-9538-3EC0089D4453Q38612977-6DBFC598-27B7-4979-81BB-815F4A4B5763Q38810636-475E8A37-0D43-4B76-B98F-60E30A1BC2E7Q38931021-5E150A34-68BF-459B-BD1A-E3C15160D29BQ38946338-3E89B1F0-2518-474C-8EDB-C6AB972A919CQ39247449-57F4BF72-4BE5-422F-98E4-0829CC83CB5CQ46409637-CDC6CB6D-8682-4177-8867-EF745A2EA4E9Q48246057-ED1B49A5-02DB-478A-988E-E72D68D011CDQ50079049-06A47CF7-D905-4E48-8F94-C42161184537Q50086043-26F85D73-91BC-45A4-BD0E-5A7EB7C8B418
P2860
Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
@en
type
label
Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
@en
prefLabel
Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
@en
P2860
P1476
Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
@en
P2093
Michele Faulkner
P2860
P304
P356
10.1517/14740338.2015.1093620
P407
P577
2015-09-22T00:00:00Z